Release date: May 25, 2017
Expiration date: May 25, 2018
This is a four-part presentation on”Navigating the Adverse Effects of ADT: Improving Patient Outcomes.”
- In the first of the four presentations, E. David Crawford, MD, will provide an introduction and discuss “Current ADT Challenges.”
- For the second, Thomas E. Keane, MD, will discuss “Bones, Hot Flashes, and ADT Use with Chemotherapy and Timing.”
- The third presentation, Neal D. Shore, MD, FACS, talks about “Other Side Effects: Perception vs Evidence.“
- In the final presentation, Jehonathan H. Pinthus, MD, PhD, FRCSC, discusses “ADT Impact on Cardiovascular Health.”
You may also download a slide deck on ADT by clicking on “Download Slides.”
Presentation & Posttest
Posttest at end of presentation
[cap_iframe_loader type=’iframe’ width=’100%’ height=’700′ frameborder=’0′ src=’https://grandroundsinurology.com/wp-content/uploads/adobe_captivate_uploads/Navigating_the_Adverse_effects_Captivate_Final/index.html’]
Faculty
Faculty
E. David Crawford, MD (Program Chair) Professor of Surgery, Urology and Radiation Oncology
E. David Crawford is Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Denver (UCD) in Denver, Colorado. He is also the E. David Crawford Endowed Chair in Urologic Oncology at UCD. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in Urology at the Good Samaritan Hospital in Cincinnati. He was subsequently awarded a Genitourinary Cancer fellowship with Dr. Donald G. Skinner at the University of California Medical Center in Los Angeles. Dr. Crawford is a nationally recognized expert in prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored more than 400 articles, which have been published in such journals as Urology, The New England Journal of Medicine, and the Journal of the National Cancer Institute. He has published five textbooks. He is also an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology. He serves as Medical Editor of Grand Rounds in Urology. Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical AUA, he is a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and he chairs the national Prostate Conditions Education Council (PCEC).
See more here! |
 Thomas E. Keane, MD
Professor and Chairman
Dr. Thomas Keane, a surgical urologic oncologist and nationally recognized researcher with previous appointments at Emory University and Grady Memorial Hospital in Atlanta, accepted the position of Chairman of Urology at MUSC. Dr. Keane obtained his medical degree in Ireland and completed 7 years of general surgery before obtaining a research fellowship at Duke University which led to a urologic residency. He is currently a Professor of Urology and holds the Brockmann Chair in Urologic Oncology. An avid researcher, he has served as principal investigator/co-investigator on more than 20 major clinical/pre-clinical studies. His work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a number of U.S. patents. Dr. Keane has published over 100 articles peer-reviewed in such journals as The Journal of Urology, Journal of Clinical Investigation, and Cancer Research. He provides editorial services to numerous urology journals and is coeditor of the text Glenn’s Urologic Surgery. Dr. Keane has chaired the renal section of the Eastern Cooperative Oncology Group and is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.
See more here! |
Neal D. Shore, MD, FACS
Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, and the Large Urology Group Practice Association. He also is a member of the AUA Data Committee, the Bladder Cancer Advocacy Think Tank and the editorial board of Urology Times. He has numerous articles/peer reviewed publications and also performs peer review for more multiple journals. |
Jehonathan Pinthus, MD, PhD, FRCSC
McMaster University Hamilton, ON, Canada Jehonathan Pinthus MD, PhD is an Associate Professor in the Department of Surgery Division of Urology McMaster University. He is a surgical oncologist-Urologist who completed his MD at the Hebrew University in Jerusalem Israel and his Urology training at the Sheba Medical Centre Tel Aviv University Israel. He then completed 2.5 years of SUO- accredited fellowship in Uro-Oncology in the University of Toronto. Dr. Pinthus earned his PhD at the Weizmann Institute of Science working on gene immunotherapy of prostate cancer. He is heading a basic and translational research laboratory at McMaster University and his research interests relates to the patients individual host factors and metabolism that affects prostate cancer growth and response to therapy. Dr. Pinthus published more than 80 peer reviewed papers, several book chapters and is a member of the editorial board of European Urology and Prostate Cancer and Prostatic Disease journals. Dr. Pinthus is the principle investigator on many distinguished research grants the most recent one is a $3.5 M Movember-Prostate Cancer Canada grant titled ” Role of androgen deprivation therapy in cardiovascular disease – a longitudinal prostate cancer study (RADICAL PC)” to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease.
See more here! |